BPH Nodules: Causes, Symptoms, and Management Options

Benign prostatic hyperplasia (BPH) nodules are clusters of overgrown tissue that form inside the prostate gland, gradually squeezing the urethra and making it harder to urinate. They are composed of a mix of stromal (connective) and glandular cells, and they develop almost exclusively in the transition zone of the prostate, the ring of tissue surrounding the urethra. BPH nodules are not cancerous, but the symptoms they produce can range from a mild annoyance to a serious drain on quality of life, and in some cases they lead to complications that require treatment.

What BPH Nodules Actually Are

The prostate is roughly walnut-sized in a young man, and it sits just below the bladder, wrapping around the urethra like a doughnut. BPH nodules are well-defined lumps of tissue that grow within that doughnut, and under a microscope they show both stromal and glandular components.¹ Not all nodules are the same, though. Nodules that form close to the urethra (periurethral nodules) tend to be mostly stromal, meaning they are made up of smooth muscle and connective tissue. Nodules that form in the broader transition zone are almost always glandular, built from newly sprouting duct branches.² This distinction matters because the composition of the nodules can influence which treatments work best.

The periurethral stromal nodules have drawn particular attention from researchers because, under the microscope, they resemble tissue from the developing prostate during embryonic life. This led to a long-standing hypothesis that BPH involves a kind of reawakening of dormant embryonic growth signals. In other words, cells that were supposed to stop multiplying decades ago start behaving as if the prostate is still being built.

What Causes BPH Nodules to Form

For years, testosterone was treated as the main villain in prostate growth. The reality is more nuanced. Testosterone itself is not the direct driver. Inside prostate cells, an enzyme called 5-alpha-reductase converts testosterone into dihydrotestosterone (DHT), a more potent hormone that binds to receptors in the prostate and stimulates cell growth. It is this locally produced DHT, combined with chronic low-grade inflammation in the tissue, that promotes the nodular proliferation of stromal and glandular cells.³ Researchers have increasingly argued that androgens alone are not the root cause of BPH; rather, it is the interplay between DHT and inflammatory damage inside the gland that tips the balance toward growth.

Beyond hormones, metabolic health plays a meaningful role. Conditions grouped under “metabolic syndrome,” including insulin resistance, excess abdominal fat, and abnormal cholesterol levels, are associated with larger prostate volumes. A meta-analysis found that men with metabolic syndrome had significantly higher total prostate volume than men without it, and the difference was most pronounced in older, heavier men with low levels of HDL cholesterol.⁴ The exact pathway linking metabolic syndrome to prostate growth is still being untangled, but insulin resistance, inflammatory signaling, and shifts in sex hormone balance all appear to contribute.⁵

The Genetic Side of the Story

Family history is one of the strongest and most overlooked risk factors for BPH. Genetic predisposition is estimated to account for somewhere between 40% and 70% of BPH cases and associated voiding symptoms.⁶ A landmark case-control study found that male relatives of men who had early-onset BPH carried a cumulative lifetime risk of needing prostate surgery of about 66%, compared to 17% in control families. Brothers of affected men faced a six-fold increase in risk. Segregation analysis suggested that a dominant gene associated with early onset of BPH was the best explanation for this clustering.⁷

More recent genome-wide studies have estimated the heritability of BPH at roughly 0.56 to 0.65, meaning that a majority of the variation in risk across the population can be attributed to genetic differences. Chromosomes 6 and 7 have emerged as likely locations for susceptibility genes, and a variant on chromosome 22 in a gene called SYN3 showed the strongest individual signal in one large analysis.⁸ None of this means BPH is destiny if your father had it, but it does mean that a strong family history is a genuine reason to pay attention to early symptoms rather than dismiss them.

Symptoms That BPH Nodules Produce

The nodules themselves are painless. The symptoms come from the mechanical obstruction they create as they press against the urethra and from the secondary changes they trigger in the bladder. Urologists divide these symptoms into three categories:

• Voiding symptoms: A weak or interrupted stream, straining to start urination, a sense that the bladder has not fully emptied, and dribbling at the end.
• Storage symptoms: Needing to urinate more frequently during the day, waking multiple times at night (nocturia), sudden urgency, and sometimes urgency incontinence.⁹
• Post-micturition symptoms: A feeling of incomplete emptying or continued dribbling after finishing.¹⁰

Many men assume that a weak stream is the hallmark BPH symptom, and it is the most recognizable one. But storage symptoms, particularly nocturia and urgency, often cause the most distress in daily life. Multiple trips to the bathroom at night disrupt sleep, and unpredictable urgency can make social outings stressful. A large survey found that men who experienced all three symptom categories together reported the lowest quality-of-life scores, with about 36% screening positive for clinical anxiety and about 30% screening positive for clinical depression.¹¹ Nocturia and urgency were among the strongest predictors of anxiety in men.

How the Bladder Responds to Obstruction

BPH nodules do not just narrow the urethra. Over time, the bladder itself changes in response to pushing urine through a tighter opening. When the bladder has to generate higher pressure to empty, the smooth muscle cells in the bladder wall sense that mechanical stretch and alter their gene expression and protein production.¹² Initially, the bladder muscle thickens and becomes stronger, a compensatory phase where it can still empty effectively despite the obstruction. But with sustained blockage, the wall stiffens with excess connective tissue, nerve networks degrade, and the bladder loses its ability to contract properly. A systematic review described this as a three-stage process: hypertrophy, compensation, and eventually decompensation, with changes affecting the lining, the muscle layer, and the nerve supply.¹³

This bladder remodeling is the reason urologists sometimes push for treatment even when symptoms feel tolerable. Once the bladder has decompensated, simply removing the obstruction may not fully restore normal function. The damage has been done upstream.

Diagnosis and Telling BPH Apart From Cancer

The initial workup for suspected BPH is straightforward: a medical history, a questionnaire scoring symptom severity (the International Prostate Symptom Score, or IPSS), a digital rectal exam, and often a blood test for prostate-specific antigen (PSA). The catch is that PSA levels can be elevated both by BPH and by prostate cancer, and neither PSA nor a rectal exam is particularly good at distinguishing between the two on its own.¹⁴ This overlap leads to a significant number of men being referred for biopsies they do not ultimately need.

MRI has become increasingly useful in this situation. It provides detailed images that can help differentiate BPH nodules from suspicious cancerous lesions, estimate the total and zonal volumes of the prostate, and even characterize the ratio of stromal to glandular tissue in the nodules.¹⁵ A prostate that is mostly glandular behaves differently from one that is mostly stromal, and knowing the makeup can guide treatment choices. Uroflow testing and bladder ultrasound to check how much urine remains after voiding round out the evaluation in many cases.

Medications as First-Line Treatment

Most men with bothersome BPH symptoms start with medication. The two main drug classes target different parts of the problem. Alpha-blockers, such as tamsulosin, relax the smooth muscle in the prostate and bladder neck, making it physically easier for urine to flow. They work quickly, often improving symptoms within days to weeks. The second class, 5-alpha-reductase inhibitors (5-ARIs) like finasteride and dutasteride, block the conversion of testosterone to DHT, which shrinks the gland over several months.¹⁶ Both dutasteride and finasteride have been shown to reduce prostate volume with no significant difference between them.¹⁷

The important distinction between these two classes is what they do over the long haul. Alpha-blockers relieve symptoms but do not change the underlying growth trajectory. They do not shrink the prostate, reduce the risk of acute urinary retention, or lower the chances of eventually needing surgery. 5-ARIs do all three, but they take months to kick in and can cause side effects like reduced libido and erectile changes. For men at higher risk of disease progression, particularly those with larger prostates, combining an alpha-blocker with a 5-ARI has shown clear advantages.¹⁸ In a study with a decade of follow-up, men on combination therapy had a roughly 80% lower rate of acute urinary retention and about 62% fewer BPH-related surgeries compared to those on an alpha-blocker alone.¹⁹ A recent review confirmed that combinations involving alpha-blockers and 5-ARIs produced greater improvements in urinary flow and symptom scores than either drug alone.²⁰

Surgical Options for Larger or More Stubborn Cases

When medications stop working, cause intolerable side effects, or the prostate is simply too large for drugs to manage effectively, surgery enters the conversation. The traditional benchmark procedure is transurethral resection of the prostate (TURP), in which a surgeon threads an instrument up the urethra and shaves away obstructing tissue. TURP works well for symptom relief, but it carries a higher risk of complications such as bladder neck contracture, early urinary incontinence, and bleeding that requires transfusion.

Holmium laser enucleation (HoLEP) has emerged as a strong alternative. A meta-analysis comparing HoLEP to TURP for prostates under 100 grams found that HoLEP was associated with less blood loss, lower transfusion rates, shorter catheter time, and shorter hospital stays, though it does take longer in the operating room.²¹ For larger prostates over 60 grams, a randomized trial confirmed these advantages but noted that postoperative discomfort during urination (dysuria) was more common after HoLEP.²² A comparison of TURP, photoselective vaporization (PVP, also called Greenlight laser), and HoLEP for smaller prostates found that laser-based approaches were preferable for men with certain risk factors such as diabetes or existing bladder muscle weakness.²³

Minimally Invasive Procedures That Preserve Sexual Function

One of the biggest concerns men have about BPH treatment is the effect on sexual function. TURP and even some medications can cause retrograde ejaculation (where semen goes into the bladder instead of out) or erectile changes. A newer generation of minimally invasive procedures has been designed specifically to address BPH while minimizing these risks.

Rezūm (water vapor thermal therapy) uses steam injections to destroy obstructing prostate tissue. Across multiple studies, it typically reduces symptom scores by at least half and improves peak urinary flow by 4 to 5 mL/s. Five-year follow-up data show that these improvements hold up over time, with retreatment rates of only about 4 to 5%.²⁴ The procedure can be performed under local anesthesia, and it preserves erectile and ejaculatory function in most men. UroLift, which uses small implants to hold prostate lobes apart, has shown similar durability at five years for sexual function preservation.²⁵

A systematic review and meta-analysis of minimally invasive therapies collectively found statistically significant improvements in erectile function scores and reductions in ejaculatory bother at 12 months.²⁶ These procedures do not remove as much tissue as TURP or HoLEP, so they may not be sufficient for very large prostates or severe obstruction. But for men with moderate symptoms who place a high value on preserving sexual function, they fill a gap that medications and traditional surgery cannot.

Prostatic Artery Embolization

Prostatic artery embolization (PAE) is one of the newer entrants into BPH management, performed by interventional radiologists rather than urologists. The procedure involves threading a tiny catheter through the wrist or groin into the arteries that feed the prostate, then injecting microscopic particles to block blood flow. The resulting tissue shrinkage reduces obstruction. A study reporting ten years of experience with PAE found mean symptom score improvements of about 16 points on the IPSS scale, a roughly 39% reduction in prostate volume, and a 155% improvement in peak urinary flow rate.²⁷ PAE is generally performed as a day procedure and recovery is quick, though it is not yet as widely available as TURP or HoLEP, and its place in treatment guidelines is still evolving.

What Happens If BPH Goes Untreated

Mild BPH that does not bother you much can reasonably be monitored with regular checkups, a strategy urologists call watchful waiting. But progressive obstruction that goes unaddressed can lead to serious downstream problems. Roughly half of men with BPH develop noticeable prostate enlargement, and about half of those eventually experience significant obstruction with high bladder pressures and reduced flow. The complications that follow can include acute urinary retention (a sudden inability to urinate, which is a medical emergency), chronic retention, recurrent urinary tract infections, bladder stones, blood in the urine, and bladder wall damage from years of straining.²⁸

In the most severe cases, chronically high bladder pressures can back up into the kidneys. Large residual urine volumes (over about 300 mL), combined with an unstable or stiffened bladder, have been associated with chronic renal failure. The most commonly proposed mechanism is that the bladder, remodeled by years of obstruction, physically blocks drainage from the ureters where they connect to the bladder.²⁹ Kidney damage from BPH is uncommon but not rare, and it develops silently, which is why doctors monitor kidney function in men with known severe obstruction.

Lifestyle Factors and Nutritional Supplements

No diet or supplement will make BPH nodules disappear, but lifestyle choices can influence how symptomatic they become. Regular moderate exercise has a well-documented association with less severe BPH symptoms, likely mediated in part through its effects on insulin sensitivity, inflammation, and hormone levels. The type and amount of protein you eat also appears to matter. A review of nutritional influences on BPH found that exercise, adequate zinc and vitamin D intake, and certain plant-based supplements, particularly saw palmetto, cernilton (a pollen extract), and pygeum, had positive effects on symptoms.³⁰ The evidence for these supplements is mixed in quality: saw palmetto, for instance, has performed well in some smaller trials but failed to beat placebo in larger, more rigorous ones. They are worth discussing with a doctor as an add-on rather than a replacement for proven medical therapy.

Weight management ties back to the metabolic risk factors discussed earlier. Reducing visceral fat, improving insulin sensitivity, and keeping cholesterol in a healthy range may slow prostate growth over time. These are not quick fixes, but they are changes that benefit multiple systems beyond the prostate.

Dogs, BPH, and Why It Matters for Research

Humans are not the only species that develops BPH naturally. Intact male dogs are one of the few animals that develop spontaneous prostatic hyperplasia as they age, making them a valuable research model. The canine version comes in two forms: a purely glandular type and a “complex” form seen in older dogs that includes both glandular overgrowth and increased stromal components, closely mirroring the mixed nodules seen in human BPH.³¹ Researchers have used beagles with spontaneous BPH to test procedures like prostatic artery embolization before bringing them to human trials, screening dogs by ultrasound and performing the same catheter-based interventions used in people.³² The fact that dogs develop BPH without any genetic engineering or hormonal manipulation means findings from canine studies are more likely to translate meaningfully to the human condition than studies using artificially induced models in rodents.